Urogen Pharma Ltd
(URGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 21,848 | 18,781 | 23,530 | 20,852 | 21,139 |
| Cost of Goods | 2,229 | 1,728 | 2,286 | 2,367 | 2,443 |
| Gross Profit | 19,619 | 17,053 | 21,244 | 18,485 | 18,696 |
| Operating Expenses | 45,687 | 43,521 | 36,139 | 32,352 | 34,521 |
| Operating Income | -25,839 | -25,740 | -14,609 | -13,500 | -15,382 |
| Interest Expense | 3,461 | 2,447 | 3,586 | 3,815 | 3,761 |
| Other Income | -4,065 | -4,045 | -3,967 | -4,573 | -4,939 |
| Pre-tax Income | -33,365 | -32,232 | -22,162 | -21,888 | -24,082 |
| Income Tax | 38 | 54 | 3,854 | -9 | 54 |
| Net Income Continuous | -33,403 | -32,286 | -26,016 | -21,879 | -24,136 |
| Net Income | $-33,403 | $-32,286 | $-26,016 | $-21,879 | $-24,136 |
| EPS Basic Total Ops | -0.82 | -0.87 | -0.54 | -0.68 | -1.03 |
| EPS Basic Continuous Ops | -0.82 | -0.87 | -0.54 | -0.68 | -1.03 |
| EPS Diluted Total Ops | -0.82 | -0.87 | -0.54 | -0.68 | -1.03 |
| EPS Diluted Continuous Ops | -0.82 | -0.87 | -0.54 | -0.68 | -1.03 |
| EPS Diluted Before Non-Recurring Items | -0.91 | -0.97 | -0.72 | N/A | N/A |
| EBITDA(a) | $-26,067 | $-25,800 | $-14,831 | $-13,272 | $-15,483 |